Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2020

01-01-2020 | Endoscopy | CURRENT CLINICAL CONTROVERSY

Time to Challenge Current Strategies for Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma

Authors: David A. Katzka, Rebecca C. Fitzgerald

Published in: Digestive Diseases and Sciences | Issue 1/2020

Login to get access

Excerpt

Adenocarcinoma of the esophagus (EAC) is a disease with a high mortality rate since initial detection usually occurs at an advanced stage in the majority of patients [1]. For example, data demonstrate that 50% of patients are diagnosed at stage II or higher with 20% diagnosed with stage IV disease [2]. As a result, even in this decade, the overall 5-year survival for EAC remains under 25% [2], despite increased efforts directed at increasing physician and patient awareness, multiple published society guidelines, and advances in endoscopic procedural quality and imaging. That the survival of EAC has not changed appreciably over the past two decades implies that a fundamental issue is not being addressed regarding the pathophysiology and classification of EAC. In this article, we will attempt to identify some of these issues. …
Literature
1.
go back to reference Dubecz A, Gall I, Solymosi N, et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol. 2012;7:443–447.CrossRef Dubecz A, Gall I, Solymosi N, et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol. 2012;7:443–447.CrossRef
2.
go back to reference Tramontano AC, Sheehan DF, Yeh JM, et al. The impact of a prior diagnosis of Barrett’s esophagus on esophageal adenocarcinoma survival. Am J Gastroenterol. 2017;112:1256–1264.CrossRef Tramontano AC, Sheehan DF, Yeh JM, et al. The impact of a prior diagnosis of Barrett’s esophagus on esophageal adenocarcinoma survival. Am J Gastroenterol. 2017;112:1256–1264.CrossRef
3.
go back to reference Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.CrossRef Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.CrossRef
4.
go back to reference Visrodia K, Singh S, Krishnamoorthi R, et al. Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2016;44:775–784.CrossRef Visrodia K, Singh S, Krishnamoorthi R, et al. Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2016;44:775–784.CrossRef
5.
go back to reference Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–25.CrossRef Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–25.CrossRef
6.
go back to reference Sawas T, Killcoyne S, Iyer PG, et al. Identification of prognostic phenotypes of esophageal adenocarcinoma in 2 independent cohorts. Gastroenterology. 2018;155:1720–1728. (e1724).CrossRef Sawas T, Killcoyne S, Iyer PG, et al. Identification of prognostic phenotypes of esophageal adenocarcinoma in 2 independent cohorts. Gastroenterology. 2018;155:1720–1728. (e1724).CrossRef
7.
go back to reference Leers JM, DeMeester SR, Chan N, et al. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg. 2009;138:594–602. (discussion 601-592).CrossRef Leers JM, DeMeester SR, Chan N, et al. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg. 2009;138:594–602. (discussion 601-592).CrossRef
8.
go back to reference Hamade N, Vennelaganti S, Parasa S, et al. Lower annual rate of progression of short-segment vs long-segment Barrett’s esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2019;17:864–868.CrossRef Hamade N, Vennelaganti S, Parasa S, et al. Lower annual rate of progression of short-segment vs long-segment Barrett’s esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2019;17:864–868.CrossRef
9.
go back to reference Visrodia K, Singh S, Krishnamoorthi R, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology. 2015;150:599–607.CrossRef Visrodia K, Singh S, Krishnamoorthi R, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology. 2015;150:599–607.CrossRef
10.
go back to reference Gaddam S, Singh M, Balasubramanian G, et al. Persistence of nondysplastic Barrett’s esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology. 2013;145:548–553. (e541).CrossRef Gaddam S, Singh M, Balasubramanian G, et al. Persistence of nondysplastic Barrett’s esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology. 2013;145:548–553. (e541).CrossRef
11.
go back to reference Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1046–1055. (e1048).CrossRef Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1046–1055. (e1048).CrossRef
12.
go back to reference Asge Standards of Practice C, Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90:335–359. (e332).CrossRef Asge Standards of Practice C, Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90:335–359. (e332).CrossRef
13.
go back to reference Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76:531–538.CrossRef Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76:531–538.CrossRef
14.
go back to reference Rubenstein JH, Thrift AP. Risk factors and populations at risk: selection of patients for screening for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:41–50.CrossRef Rubenstein JH, Thrift AP. Risk factors and populations at risk: selection of patients for screening for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:41–50.CrossRef
15.
go back to reference Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75:945–953. (e942).CrossRef Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75:945–953. (e942).CrossRef
16.
go back to reference Honing J, Kievit W, Bookelaar J, Peters Y, Iyer PG, Siersema PD. Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett’s esophagus in patients with GERD symptoms. Gastrointest Endosc. 2018;89:712–722.CrossRef Honing J, Kievit W, Bookelaar J, Peters Y, Iyer PG, Siersema PD. Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett’s esophagus in patients with GERD symptoms. Gastrointest Endosc. 2018;89:712–722.CrossRef
17.
go back to reference Sami SS, Dunagan KT, Johnson ML, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community. Am J Gastroenterol. 2015;110:148–158.CrossRef Sami SS, Dunagan KT, Johnson ML, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community. Am J Gastroenterol. 2015;110:148–158.CrossRef
18.
go back to reference Gora MJ, Sauk JS, Carruth RW, et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med. 2013;19:238–240.CrossRef Gora MJ, Sauk JS, Carruth RW, et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med. 2013;19:238–240.CrossRef
20.
go back to reference Chandar AK, Devanna S, Lu C, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:2241–2255. (e2244).CrossRef Chandar AK, Devanna S, Lu C, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:2241–2255. (e2244).CrossRef
21.
go back to reference Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut. 2018;67:1942–1949.CrossRef Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut. 2018;67:1942–1949.CrossRef
22.
go back to reference Elliott DRF, Walker AW, O’Donovan M, Parkhill J, Fitzgerald RC. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol Hepatol. 2017;2:32–42.CrossRef Elliott DRF, Walker AW, O’Donovan M, Parkhill J, Fitzgerald RC. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol Hepatol. 2017;2:32–42.CrossRef
23.
go back to reference Januszewicz W, Tan WK, Lehovsky K, et al. Safety and acceptability of esophageal cytosponge cell collection device in a pooled analysis of data from individual patients. Clin Gastroenterol Hepatol.. 2019;17:647–656. (e641).CrossRef Januszewicz W, Tan WK, Lehovsky K, et al. Safety and acceptability of esophageal cytosponge cell collection device in a pooled analysis of data from individual patients. Clin Gastroenterol Hepatol.. 2019;17:647–656. (e641).CrossRef
24.
go back to reference Gharahkhani P, Fitzgerald RC, Vaughan TL, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016;17:1363–1373.CrossRef Gharahkhani P, Fitzgerald RC, Vaughan TL, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016;17:1363–1373.CrossRef
25.
go back to reference Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological A. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–e52. (quiz e13).CrossRef Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological A. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–e52. (quiz e13).CrossRef
26.
go back to reference Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50. (quiz 51).CrossRef Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50. (quiz 51).CrossRef
27.
go back to reference Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRef Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRef
28.
go back to reference Sawas T, Manrique GC, Iyer PG, Wang KK, Katzka DA. Young adults with esophageal adenocarcinoma present with more advanced stage tumors and have shorter survival times. Clin Gastroenterol Hepatol. 2019;17:1756–1762.CrossRef Sawas T, Manrique GC, Iyer PG, Wang KK, Katzka DA. Young adults with esophageal adenocarcinoma present with more advanced stage tumors and have shorter survival times. Clin Gastroenterol Hepatol. 2019;17:1756–1762.CrossRef
29.
go back to reference Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).CrossRef Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).CrossRef
30.
go back to reference Chen Q, Zhuang H, Liu Y. The association between obesity factor and esophageal caner. J Gastrointest Oncol. 2012;3:226–231.PubMedPubMedCentral Chen Q, Zhuang H, Liu Y. The association between obesity factor and esophageal caner. J Gastrointest Oncol. 2012;3:226–231.PubMedPubMedCentral
31.
go back to reference Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomark Prev. 2008;17:352–358.CrossRef Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomark Prev. 2008;17:352–358.CrossRef
32.
go back to reference Fang TC, Oh YS, Szabo A, Khan A, Dua KS. Utility of dysphagia grade in predicting endoscopic ultrasound T-stage of non-metastatic esophageal cancer. Dis Esophagus Off J Int Soc Dis Esophagus ISDE. 2015;29:642–648.CrossRef Fang TC, Oh YS, Szabo A, Khan A, Dua KS. Utility of dysphagia grade in predicting endoscopic ultrasound T-stage of non-metastatic esophageal cancer. Dis Esophagus Off J Int Soc Dis Esophagus ISDE. 2015;29:642–648.CrossRef
33.
go back to reference Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.CrossRef Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.CrossRef
Metadata
Title
Time to Challenge Current Strategies for Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma
Authors
David A. Katzka
Rebecca C. Fitzgerald
Publication date
01-01-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05965-0

Other articles of this Issue 1/2020

Digestive Diseases and Sciences 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.